eFFECTOR Enters Into Agreement with Pfizer Inc. to Develop Novel First-in-Class Inhibitors of eIF4E to Treat Multiple Cancer Types

by NASDAQ Market News January 9, 2020

NASDAQ Market News
Click here to email author

NeoTherma Oncology Announces FDA IDE Submission to Permit Investigational Treatment of Pancreatic Cancer Patients with Its FDA-Designated Breakthrough Device, the VectRx™ Thermal Oncology System

Zai Lab and Novocure Announce First Patient Enrolled in a Phase 2 Pilot Trial of Tumor Treating Fields Together with Chemotherapy as First-Line Treatment of Gastric Cancer

Ads